CardioWise™ Receives US FDA 510(k) Clearance for Str

CardioWise™ Receives US FDA 510(k) Clearance for Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Heart Function Analysis Software


CardioWise™ Receives US FDA 510(k) Clearance for Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) Heart Function Analysis Software
Share Article
CardioWise, Inc., is pleased to announce Clearance of its 510(k) application by the US Food and Drug Administration (FDA) for its heart function analysis software, Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ).
"CardioWise can now market the SQuEEZ analysis to provide give caregivers an easy-to-read, quantitative 4D color model that allows physicians to make better, more informed decisions about their patients’ care.” -Jack Coats, CEO of CardioWise, Inc.
FAYETTEVILLE, Ark. (PRWEB)
January 06, 2021
The 510(k) premarket notification letter indicates that the FDA has determined that SQuEEZ may be legally marketed in interstate commerce according to its indications for use. SQuEEZ is an image analysis software application for cardiac Computer Tomography (CT) studies to assist cardiologists and radiologists in assessing function when producing a cardiac evaluation. The software calculates a Stretch Quantifier for Endocardial Engraved Zones (SQuEEZ) value to highlight and color code motions of the heart wall. Additional tools are provided to display regional motion properties of the heart.

Related Keywords

Geoffrey Dalbow , Cardiowise Inc , Technology Venture Development , Jack Coats , Computer Tomography , Stretch Quantifier , Endocardial Engraved Zones , Cardiovascular Disease , Cardiowise Engineering , Chief Technology Officer , Johns Hopkins , Venture Development , தொழில்நுட்பம் துணிகர வளர்ச்சி , பலா கோட்டுகள் , கணினி டோமோகிராபி , இருதய நோய் , தலைமை தொழில்நுட்பம் அதிகாரி , ஜான்ஸ் ஹாப்கின்ஸ் , துணிகர வளர்ச்சி ,

© 2025 Vimarsana